Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

514.26
+3.880.76%
Volume:25.11K
Turnover:12.92M
Market Cap:22.06B
PE:18.40
High:517.59
Open:514.20
Low:512.55
Close:510.38
52wk High:609.35
52wk Low:375.61
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.81
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.45
PE(LYR):18.46

Loading ...

Nov 24, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 24, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 19, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 18, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 17, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 17, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Nov 03, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 03, 2021

Major Issues Report

8-K - Current report
Oct 18, 2021

Major Issues Report

8-K - Current report
Oct 01, 2021

Major Issues Report

8-K - Current report
Aug 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 04, 2021

Major Issues Report

8-K - Current report
Aug 04, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Jun 25, 2021

Major Issues Report

8-K - Current report
Jun 23, 2021

Major Issues Report

8-K - Current report
Jun 16, 2021

Major Issues Report

8-K - Current report
Jun 07, 2021

Major Issues Report

8-K - Current report
Jun 03, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Major Issues Report

8-K - Current report
May 05, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]